Infliximab induces a dysregulated tissue-homing profile on human T-lymphocytes in-vitro: A novel mechanism for paradoxical inflammation?

Journal of Crohn's and Colitis

Volumn 7, Issue 9, 2013, Pages 765-767

  Peake, Simon T ^a,b   Bernardo, David ^a   Mann, Elizabeth R ^a   Al Hassi, Hafid O ^a   Knight, Stella C ^a   Hart, Ailsa L ^a,b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b ST MARK S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CCR7; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

AUTOIMMUNITY; CHEMICAL PARAMETERS; DRUG EFFICACY; DRUG SAFETY; ENTERITIS; HUMAN; IN VITRO STUDY; INFLAMMATION; INFLAMMATORY DISEASE; LETTER; LEUKOCYTE MIGRATION; PRIORITY JOURNAL; SKIN DISEASE; TISSUE HOMING;

ANTIBODIES, MONOCLONAL; B7 ANTIGENS; CELLS, CULTURED; GASTROINTESTINAL AGENTS; HUMANS; INFLAMMATION; RECEPTORS, CCR4; RECEPTORS, CCR7; RECEPTORS, LYMPHOCYTE HOMING; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84881544567     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2013.01.001     Document Type: Letter

References (11)

1. Chowers Y., Sturm A., Sans M., et al. Report of the ECCO workshop on anti-TNF therapy failures in inflammatory bowel diseases: biological roles and effects of TNF and TNF antagonists. J Crohns Colitis 2010, 4:367-376.
2. Rahier J.F., Buche S., Peyrin-Biroulet L., et al. Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy. Clin Gastroenterol Hepatol 2010, 8:1048-1055.
3. Fidder H., Schnitzler F., Ferrante M., et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut 2009, 58:501-508.
4. Esmailzadeh A., Yousefi P., Farhi D., et al. Predictive factors of eczema-like eruptions among patients without cutaneous psoriasis receiving infliximab: a cohort study of 92 patients. Dermatology 2009, 219:263-267.
5. Toussirot E., Houvenagel E., Goeb V., et al. Development of inflammatory bowel disease during anti-TNF-alpha therapy for inflammatory rheumatic disease. A nationwide series. Joint Bone Spine 2012, 79:457-463.
6. Palucka A.K., Blanck J.P., Bennett L., Pascual V., Bacnhereau J. Cross-regulation of TNF and IFN-alpha in autoimmune diseases. Proc Natl Acad Sci USA 2005, 102:3372-3377.
7. de Gannes G.C., Ghoreishi M., Pope J., et al. Psoriasis and pustular dermatitis triggered by TNF-{alpha} inhibitors in patients with rheumatologic conditions. Arch Dermatol 2007, 143:223-231.
8. Vermiere S., et al. Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study. Gastroenterology 2003, 125:32-39.
9. LeFrancois L., Parker C.M., Olson S., et al. The role of beta7 integrins in CD8 T-cell trafficking during an antiviral immune response. J Exp Med 1999, 189(10):1631-1638.
10. Campbell J.J., Haraldsen G., Pan J., et al. The chemokine receptor CCR4 in vascular recognition by cutaneous gut not intestinal memory T cells. Nature 1999, 400(6746):776-780.
11. Mann E.R., McCarthy N.E., Peake S.T., et al. Skin- and gut-homing molecules on human circulating γδ T-cells and their dysregulation in inflammatory bowel disease. Clin Exp Immunol 2012, 170(2):122-130.